Navigation Links
Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
Date:4/8/2009

AMSTERDAM, April 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its potential in mismatched bone marrow transplantations. Data was presented by the company's principal investigator Dr. Denis Claude Roy during the prestigious Presidential Symposium at the Annual European Bone Marrow Transplantation meeting (EBMT) in Goteborg, Sweden, on Monday, March 30, 2009. Only the 6 highest ranked presentations, representing the most promising new developments in the transplantation field, were selected for this Symposium.

ATIR(TM), a donor lymphocyte cell based preparation depleted of allo-reactive T-cells, is under development to prevent acute Graft versus Host Disease (GvHD) and allow for early immune reconstitution following a bone marrow transplantation with a fully mismatched (haplo-identical) donor.

Dr. Roy's presentation of clinical results from 19 end stage blood cancer patients with high risk leukemia and/or lymphoma using ATIR(TM) was very well received. These patients, each of whom did not have a matched donor available, were treated in a phase I/II dose escalating study with ATIR(TM) in a mismatched transplantation setting. No immune suppressants were used, which is in contrast to conventional transplant procedures. Nevertheless, no cases of severe grade III/IV acute GvHD occurred after ATIR(TM) infusion. Furthermore, the clinical data showed a reduction in the frequency of infectious episodes in the cohorts treated with the higher doses of ATIR(TM), as compared to the low dose cohorts. To date, patients in the higher dose cohorts show high survival rates (75%) with no transplant related mortality (TRM).

These results show that the selective depletion of allo-reactive T-cells in the ATIR(TM) cell based product by the proprietary photo-sensitizing agent TH9402 is highly effective and can result in fast and adequate immune reco
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
2. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
5. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
6. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
7. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
8. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
9. New Pharmaxis Board Appointment
10. Pharmaxis Investor Conference Call
11. Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The ETC (Emerging Technology Centers) ... centers, announced today that applications for AccelerateBaltimore™ (AB) ... “Do you have a big idea?,” asked ETC’s ... know about it. AccelerateBaltimore helps you and your ... just 13 weeks.” Interested game changers with ...
(Date:11/26/2014)... Charlotte, NC (PRWEB) November 25, 2014 ... High Intensity Focused Ultrasound (HIFU) devices, recently participated ... “ Small Renal Mass 360° .” Key opinion ... and therapeutic advances related to small renal masses ... learn about different ablative technologies in hands-on labs. ...
(Date:11/26/2014)... Pittsburgh, PA (PRWEB) November 25, 2014 ... release of its official conference and exposition mobile app, ... available for free download in the App Store for ... as a valuable resource tool before, during and after ... guide containing details on exhibiting companies, technical sessions, Conferee ...
(Date:11/26/2014)... 2014 SoundConnect , an award ... to announce that Darren Suders has joined the team ... will drive the partner program through innovative ... , Darren brings more than 10-years of channel ... in channel operations, from policy development, to partner education ...
Breaking Biology Technology:AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2SoundConnect Appoints Director of Channel Development & Sales 2
... ,, BEIJING , May 24 /PRNewswire-Asia/ ... manufacturer, announced today that Mr. Weidong Yin ,Chairman, President & CEO, will ... June 2-3, 2010 in London,England . Sinovac,s presentation is scheduled for ... Eastern Time . , , , ...
... 24 Transave Inc. today announced that the United States ... patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its ... the patent will provide exclusivity for ARIKACE until October 1, ... , ...
... ... The Chinese Biopharmaceutical Association-USA (CBA) ... June 12 -13 in Maryland, US. ,The event will ... development. It will also develop a platform for communication and ...
Cached Biology Technology:Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference 2Transave Issued Key Composition of Matter Patent for ARIKACE™ 2Transave Issued Key Composition of Matter Patent for ARIKACE™ 3Chinese Biopharmaceutical Association Holds 15th Annual Conference in Rockville, MD, June 12 - 13 2Chinese Biopharmaceutical Association Holds 15th Annual Conference in Rockville, MD, June 12 - 13 3
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, a ... Internet of Things (IoT), today announced the appointment of ... operating officer. Previously a strategic advisor to the firm, ... operations. Mr. Traynor is based out of the C-Labs ... reports to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... of the past decade such as the 2003 SARS ... deaths, and the 2009 H1N1 flu pandemic that killed about ... or bacteria could spread quickly across the globe, aided by ... complex network systems such as contagion patterns and information ...
... 16, 2012, Chikyu, operations in the second part of ... Drilling Project (JFAST), achieved another objective by installing temperature ... infers the fault slipped during the 2011 Tohoku Earthquake. ... scientific drilling vessel Chikyu to meet the challenge of ...
... Using recent advances in marine biomechanics, materials science, and ... and the California Institute of Technology (Caltech) have turned ... freely swimming "jellyfish." The finding serves as a ... muscular organs and simple life forms. It also suggests ...
Cached Biology News:New model of disease contagion ranks US airports in terms of their spreading influence 2New model of disease contagion ranks US airports in terms of their spreading influence 3Return to the Japan Trench 2Return to the Japan Trench 3Artificial jellyfish swims in a heartbeat 2Artificial jellyfish swims in a heartbeat 3Artificial jellyfish swims in a heartbeat 4
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
Rab1A...
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Biology Products: